Free to read, new every week
Each week, PD Brief explains a newly published Parkinson's study in everyday language for patients, caregivers and anyone else following the research.
By Caiden Sun. 1 issue published since September 2026.
A trial of a promising GLP-1 drug, exenatide, found no benefit in treating Parkinson's Disease. Over a year later, the paper was flagged after inspectors found serious problems at one of the hospitals that ran it.
One email each time a new issue is published. It’s free, and you can unsubscribe whenever you like.
Almost done. Check your inbox for a confirmation email and click the link inside it. If you can’t find it, look in your spam or promotions folder.
Buttondown, the service PD Brief uses for email, will send you a message to confirm. Your address is only used to send you PD Brief.
Everything published so far is in the archive. If you’ve seen a study worth covering, or something here didn’t make sense, send a question or a suggestion.